Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma

Table 5 1-, 2-, 3-, 4-, and 5-year survival rates in the two groups

Time	Group	Survival		Survival rate, %	χ2	P value
		Yes	No
1 yr	A	188	24	88.67	12.227	0.018
	B	101	35	74.26
2 yr	A	169	43	79.71	12.457	0.014
	B	85	51	62.50
3 yr	A	145	67	68.39	26.490	0.013
	B	55	81	40.44
4 yr	A	115	97	54.24	21.956	0.009
	B	39	97	28.67
5 yr	A	88	124	41.51	24.596	0.006
	B	22	114	16.18

The 1-, 2-, 3-, 4-, and 5-year survival rates differed significantly between Groups A and B.